A ‘Split’ Decision: Fractionated vs Single-Fraction Radiosurgery After Brain Metastasis Resection
Among patients who underwent resection of a large (≥ 2 cm) brain metastasis, postoperative fractionated stereotactic radiosurgery (SRS) improved surgical bed control compared with single-fraction SRS without an apparent increase in toxicity. This was according to findings from the multicenter phase III Alliance A071801 trial presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.1
Postoperative SRS became a standard of care for resected brain metastases after randomized trials showed better neurocognitive function and quality of life compared with whole-brain radiation therapy and reduced surgical bed recurrence compared with observation, explained presenting author Ayal A. Aizer, MD, MHS, of Mass General Brigham, Dana-Farber Cancer Institute, and Harvard Medical School, Boston. However, he noted that both trials used single-fraction SRS, with “significantly high” 1-year surgical bed recurrence rates of approximately 40% and 28%.2,3
“After surgery for a large brain metastasis, the challenge is giving enough radiation therapy to eliminate microscopic cancer cells left behind without exposing too much healthy brain to a high single dose,” principal investigator Paul D. Brown, MD, of Mayo Clinic, Rochester, Minnesota, commented in a news release issued by ASTRO. “Dividing the radiation dose over several treatments gives healthy tissue time to recover between doses while still delivering an effective dose to the treatment area.”
As reviewed by Dr. Aizer, several retrospective studies of fractionated SRS after resection of brain metastases reported 1-year surgical bed control rates of 84% to 93%. In Alliance A071801, the rate was 87% after resection of a large brain metastasis.
“This study moves fractionated radiosurgery from a reasonable practice supported by retrospective data to one backed by a randomized phase III trial,” he said. “We now have the strongest evidence to date that three to five sessions should be considered a standard postoperative treatment for patients with larger brain metastases which are resected.”
About Alliance A071801
Alliance A071801 is the first randomized phase III trial to directly compare the two postoperative approaches. The analysis included 242 patients with one to four brain metastases, including one measuring at least 2 cm that had been completely resected, with a resulting surgical cavity measuring less than 5 cm.
Between October 2019 and October 2022, patients were randomly assigned to receive single-fraction or fractionated SRS, with stratification by age, systemic therapy regimen, and resection cavity diameter. Single-fraction SRS was delivered at 12 to 20 Gy, with lower doses for larger targets. Fractionated SRS consisted of 27 Gy in three fractions for targets smaller than 30 cm3 or 30 Gy in five fractions for larger targets. Most patients in the fractionated group (91%) received three fractions. Any unresected brain metastases were treated according to the same assigned approach.
The groups were well balanced at baseline, Dr. Aizer reported, with a median age in the early to mid-60s. Lung cancer was the most common primary tumor, and most patients had no additional unresected brain metastases.
Surgical Bed Control
With a median follow-up of approximately 4 years, the 1-year surgical bed control rate was 87% with fractionated SRS and 81% with single-fraction SRS (hazard ratio [HR] = 0.53; P = .046).
“Therefore, this study met its primary objective of demonstrating that fractionated SRS reduces the likelihood of surgical bed recurrence relative to single-fraction SRS,” Dr. Aizer said.
Failure of treated, unresected brain metastases occurred in 4% of patients who received fractionated SRS and 11% of those who received single-fraction SRS (P = .063). Additionally, 94% and 84% of patients, respectively, remained free from salvage whole-brain radiation therapy at 1 year (P = .06).
Survival and Safety
Median overall survival was 28.6 months with fractionated SRS and 20.2 months with single-fraction SRS (P = .03). In a stratified multivariable analysis adjusting for Karnofsky Performance Status, primary tumor site, sex, race, and number of unresected brain metastases, fractionated SRS remained associated with improved overall survival (HR = 0.66; P = .02).
The investigators noted that this result was unexpected and that additional analyses did not identify a clear explanation. Dr. Aizer cautioned, however, that the trial was not designed to assess overall survival and that the observation should be considered hypothesis-generating.
No meaningful differences in toxicity were observed between the groups.
Findings in Context
In the news release, Lia M. Halasz, MD, FASTRO, Chair of the ASTRO Central Nervous System Resource Panel and a radiation oncologist at Fred Hutch Cancer Center and the University of Washington in Seattle, noted that many clinicians have already adopted fractionated SRS for larger surgical cavities based on retrospective evidence. With the results of Alliance A071801, she said, “[we have] randomized evidence that the additional visits translate into a meaningful improvement in local control without a significant increase in side effects.”
Dr. Brown commented on the unexpected overall survival finding, noting that “as modern treatments help patients live longer with cancer, maintaining control of disease in the brain may play an increasingly important role in long-term outcomes.”
DISCLOSURE: The study was funded by grants from the National Institutes of Health/National Cancer Institute. Dr. Brown has served as a contributor for UpToDate. Dr. Aizer has received research funding from Varian Medical Systems and NH TherAguix/TherAguix. Dr. Halasz has received research funding from Plus Therapeutics; has served as a consultant for IBA; and has served as an editor for UpToDate.
REFERENCES
1. Brown PD, Ballman KV, Aizer AA, et al: Alliance A071801 phase III trial postoperative single fraction stereotactic radiosurgery (SRS) vs fractionated SRS (fSRS) for resected brain metastasis. 2026 ASTRO Annual Meeting. Abstract LBA 01. Presented September 28, 2026.
2. Brown PD, Ballman KV, Cerhan JH, et al: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3). Lancet Oncol 18:1049-1060, 2017.
3. Mahajan A, Ahmed S, McAleer MF, et al: Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases. Lancet Oncol 18:1040-1048, 2017.
EXPERT OPINION ON PHASE III ALLIANCE A071801 TRIAL
In the multicenter phase III Alliance A071801 trial presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, Brown et al evaluated the use of postoperative fractionated stereotactic radiosurgery (SRS) vs single-fraction SRS in patients following resection of a brain metastasis (≥ 2 cm).1 Their findings showed that fractionated SRS improved surgical bed control compared with single-fraction SRS without an apparent increase in toxicity.
New Therapies, New Technologies
The treatment of brain metastases has evolved over the years due to the constant increase in the availability of new systemic therapies and new technology. One way that new technology has influenced our approach to brain metastases is by allowing for ultraprecise delivery of radiation without directly fixating a frame to a patient’s skull, previously a mainstay of SRS. Improvements in imaging and tracking tools have allowed us to deliver radiotherapy while monitoring patient movement with onboard imaging and/or surface detection. Past trials have shown that the recurrence rate after postoperative single-session SRS for resected brain metastases was much higher for larger metastases (greater than 2.5 cm).2,3 This may be due to a variety of factors, but importantly, for larger targets, we reduce the radiation dose of SRS to avoid a higher risk of cerebral edema or radionecrosis. Thus, multiple retrospective studies over the past few decades have suggested that by fractionating SRS, we can deliver a higher biologically effective dose to the tumor bed with acceptable tolerability.
Fractionated vs Single-Session SRS
The authors are to be commended for completing the randomized phase III Alliance A071801 trial to establish that patients with resected brain metastases ≥ 2 cm have superior surgical bed control at 1 year with fractionated SRS vs single-session SRS (87% vs 81%; P = .046).1 As expected, this was also associated with a decrease in time to salvage whole-brain radiation therapy (WBRT). These patients had cavity sizes less than 5 cm and up to three unresected brain metastases that were treated as well. Fractionated and single-fraction SRS had similar rates of cerebral edema and radiation necrosis. This confirms current practice for many and will set better standards for the practice of fractionated SRS. However, the improvement in overall survival for fractionated SRS in this trial (28.6 vs 20.2 months; P = .03) was surprising, as the arms of the study were well balanced for tumor type, age, tumor size, and use of targeted therapy. Past trials, including the Mahajan and Alliance NCCTG N107C/CEC.3 trials,2,3 showed no difference in overall survival between treatment arms despite different surgical bed control. Thus, we would not have expected this degree of improvement in surgical bed control to translate to an overall survival benefit in Alliance A071801. This interesting result will need to be further investigated and explained. ν
DISCLOSURE: Dr. Halasz has received research funding from Kazia Therapeutics; has served as a consultant for IBA; and has served as an editor for UpToDate.
REFERENCES
1. Brown PD, Ballman KV, Aizer AA, et al: Alliance A071801 phase III trial postoperative single fraction stereotactic radiosurgery (SRS) vs fractionated SRS (fSRS) for resected brain metastasis. 2026 ASTRO Annual Meeting. Abstract LBA 01. Presented September 28, 2026.
2. Mahajan A, Ahmed S, McAleer MF, et al: Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1040-1048, 2017.
3. Brown PD, Ballman KV, Cerhan JH, et al: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): A multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049-1060, 2017.
Lia M. Halasz, MD, FASTRO, is Chair of the ASTRO Central Nervous System Resource Panel and a radiation oncologist at Fred Hutch Cancer Center and the University of Washington in Seattle.